Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.72 USD | -0.57% | -2.70% | -14.63% |
05-03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
05-02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.63% | 3.4B | |
+4.32% | 111B | |
+10.99% | 105B | |
-12.03% | 22.34B | |
-3.81% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-9.23% | 16.96B | |
+3.17% | 13.7B | |
+36.40% | 12.45B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Insider Sold Shares Worth $1,436,100, According to a Recent SEC Filing